Antioxidants and Redox Signaling, volume 41, issue 16-18, pages 1031-1050

A core NRF2 gene set defined through comprehensive transcriptomic analysis predicts selective drug resistance and poor multi-cancer prognosis

George Luo 1
Harshita Kumar 2, 3
Kristin Alridge 4
Kristin Aldridge 5
Stevie Rieger 4, 6
Eunhyang Han 1, 7
Ethan Jiang 8, 9
Ernest Chan 10
Ernest R Chan 11
Ahmed Soliman 12, 13
Haider Mahdi 14, 15, 16, 17
John J. Letterio 18, 19, 20, 21
Show full list: 12 authors
5
 
Triterpenoid Therapeutics Inc., Tunbridge, Vermont, USA.
12
 
SUNY Downstate Medical Center, Pediatrics, New York City, New York, United States;
13
 
Department of Pediatrics, SUNY Downstate Hospital, Brooklyn, New York, USA.
19
 
The Angie Fowler Adolescent and Young Adult Cancer Institute, University Hospitals Rainbow Babies & Children’s Hospital, Cleveland, Ohio, USA.
20
 
The Case Comprehensive Cancer Center, Cleveland, Ohio, USA.
Publication typeJournal Article
Publication date2024-12-01
scimago Q1
SJR1.708
CiteScore14.1
Impact factor5.9
ISSN15230864, 15577716

Top-30

Publishers

1
2
1
2
  • We do not take into account publications without a DOI.
  • Statistics recalculated only for publications connected to researchers, organizations and labs registered on the platform.
  • Statistics recalculated weekly.

Are you a researcher?

Create a profile to get free access to personal recommendations for colleagues and new articles.
Share
Cite this
GOST | RIS | BibTex | MLA
Found error?